home / stock / ebs / ebs news


EBS News and Press, Emergent Biosolutions Inc. From 03/20/20

Stock Information

Company Name: Emergent Biosolutions Inc.
Stock Symbol: EBS
Market: NYSE
Website: emergentbiosolutions.com

Menu

EBS EBS Quote EBS Short EBS News EBS Articles EBS Message Board
Get EBS Alerts

News, Short Squeeze, Breakout and More Instantly...

EBS - The Best Stocks To Buy - 'Is It Over?' Edition

Last week, I wrote "it's time to take a step back, breathe deep, and objectively identify money-making opportunities," and I reminded investors that "if you were in cash during the top 10 best days in the stock market over the past 20 years, then your overall return is half what it would've ...

EBS - What Are The Best Penny Stocks? 3 To Watch Right Now

Penny Stocks To Buy [or avoid] After Coronavirus Cases Top 200k The novel coronavirus has turned the market on its head. World governments are scrambling to figure out what to do next. Current remedies include city-wide shutdowns, school closures, event closures, and even an end to sports for ...

EBS - Vaxart up 64% premarket on coronavirus vaccine deal

Vaxart (NASDAQ: VXRT ) jumps  64%  premarket on robust volume in reaction to its agreement with Emergent BioSolutions (NYSE: EBS ) under which the latter will deploy its molecule-to-market contract development and manufacturing services for Vaxart's COVID-19 oral vaccine candidat...

EBS - VAXART ANNOUNCES IT ENTERED INTO AN AGREEMENT WITH EMERGENT BIOSOLUTIONS FOR THE DEVELOPMENT AND MANUFACTURING OF ORAL CORONAVIRUS (COVID-19) VACCINE CANDIDATE

SOUTH SAN FRANCISCO, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, announced today that it has entered into an agreement with Emergent BioSo...

EBS - EMERGENT BIOSOLUTIONS SIGNS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH VAXART FOR THEIR EXPERIMENTAL ORAL VACCINE CANDIDATE FOR CORONAVIRUS DISEASE

GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company, whereby Emergent has agreed to utilize its molecule-to-market contract ...

EBS - Novavax Joins Coronavirus Efforts, And Other News: The Good, Bad And Ugly Of Biopharma

Novavax Joins Coronavirus Race, Reports Full Year Results Novavax ( NVAX ) recently reported receiving a $4 million grant for aiding the development of vaccine for treating the coronavirus disease. The grant has been awarded by the Coalition for Epidemic Preparedness. The news provided...

EBS - Emergent BioSolutions (EBS) Presents At Cowen and Comapny 40th Annual Health Care Conference - Slideshow

The following slide deck was published by Emergent BioSolutions Inc. in conjunction with this Read more ...

EBS - Why These Drug Stocks Soared Today

Drug stocks soared on Friday with the overall stock market rebounding from Thursday's historic sell-off. Several also spiked near the end of the day today as President Trump held a news conference where he declared a national emergency that he said would "open up access" to up to $50 billion to ...

EBS - First American may receive coronavirus soon - Fauci

In a briefing to a House committee, NIAID head Anthony Fauci says he is "hopeful" that the first patient will receive a coronavirus vaccine in a few weeks. More news on: Novavax, Inc., Emergent BioSolutions Inc., Sanofi, Healthcare stocks news, Stocks on the move, Read more ...

EBS - Emergent BioSolutions to develop hyperimmune candidates for COVID-19

Emergent BioSolutions (NYSE: EBS ) initiates two new programs aimed at treating and preventing coronavirus infection based on its hyperimmune platforms. More news on: Emergent BioSolutions Inc., Healthcare stocks news, Stocks on the move, Read more ...

Previous 10 Next 10